GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

Speaking of Erbitux,
DARMSTADT, Germany, Jan. 05, 2009 – A study published today in the Journal of Clinical Oncology demonstrates that the addition of Erbitux® (cetuximab) to standard oxaliplatin-based chemotherapy (FOLFOX-4) in previously untreated metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors results in significantly higher efficacy than chemotherapy alone. The OPUSa study demonstrated a remarkably high response rate (RR) of 61%, clearly exceeding that seen in patients treated with chemotherapy alone (RR 37%, p=0.011).

http://pharmalive.com/news/index.cfm?articleID=595317&categoryid=48